MXPA04007732A - Celulas madre similares a las embrionarias, derivadas de la placenta de mamiferos despues del parto y usos y metodos de tratamiento usando dichas celulas. - Google Patents

Celulas madre similares a las embrionarias, derivadas de la placenta de mamiferos despues del parto y usos y metodos de tratamiento usando dichas celulas.

Info

Publication number: MXPA04007732A
Authority: MX; Mexico
Prior art keywords: cells; stem cells; embryonic; stem; administration
Prior art date: 2002-02-13

Application number

MXPA04007732A

Other languages

English (en)

Spanish (es)

Inventor

J Hariri Robert

Original Assignee

Anthrogenesis Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-13

Filing date

2003-02-13

Publication date

2004-10-15

2002-02-13 Priority claimed from US10/076,180 external-priority patent/US20030032179A1/en

2003-02-13 Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp

2004-10-15 Publication of MXPA04007732A publication Critical patent/MXPA04007732A/es

Links

210000000130 stem cell Anatomy 0.000 title claims abstract description 612
238000000034 method Methods 0.000 title claims abstract description 235
238000011282 treatment Methods 0.000 title claims abstract description 38
210000004027 cell Anatomy 0.000 title claims description 474
210000004993 mammalian placenta Anatomy 0.000 title 1
210000004700 fetal blood Anatomy 0.000 claims abstract description 155
210000002826 placenta Anatomy 0.000 claims abstract description 133
239000000203 mixture Substances 0.000 claims abstract description 80
241000282414 Homo sapiens Species 0.000 claims abstract description 55
210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 45
210000001185 bone marrow Anatomy 0.000 claims abstract description 43
230000001605 fetal effect Effects 0.000 claims abstract description 16
230000006806 disease prevention Effects 0.000 claims abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 83
210000004369 blood Anatomy 0.000 claims description 54
239000008280 blood Substances 0.000 claims description 54
239000003102 growth factor Substances 0.000 claims description 53
230000004069 differentiation Effects 0.000 claims description 52
201000010099 disease Diseases 0.000 claims description 45
208000035475 disorder Diseases 0.000 claims description 38
210000001671 embryonic stem cell Anatomy 0.000 claims description 37
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 34
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 34
208000014674 injury Diseases 0.000 claims description 27
230000024245 cell differentiation Effects 0.000 claims description 21
230000006378 damage Effects 0.000 claims description 21
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 19
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 19
230000008733 trauma Effects 0.000 claims description 19
102000015696 Interleukins Human genes 0.000 claims description 16
108010063738 Interleukins Proteins 0.000 claims description 16
238000002156 mixing Methods 0.000 claims description 15
210000003954 umbilical cord Anatomy 0.000 claims description 15
210000000601 blood cell Anatomy 0.000 claims description 14
230000003169 placental effect Effects 0.000 claims description 12
206010061218 Inflammation Diseases 0.000 claims description 11
208000027418 Wounds and injury Diseases 0.000 claims description 11
210000002950 fibroblast Anatomy 0.000 claims description 11
230000004054 inflammatory process Effects 0.000 claims description 11
-1 lymphokine Proteins 0.000 claims description 9
101800003838 Epidermal growth factor Proteins 0.000 claims description 8
229940116977 epidermal growth factor Drugs 0.000 claims description 8
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 8
102100032912 CD44 antigen Human genes 0.000 claims description 7
102000004127 Cytokines Human genes 0.000 claims description 7
108090000695 Cytokines Proteins 0.000 claims description 7
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 7
101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 7
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 7
101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 7
102100025304 Integrin beta-1 Human genes 0.000 claims description 7
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 7
102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 7
108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 7
102000003729 Neprilysin Human genes 0.000 claims description 7
108090000028 Neprilysin Proteins 0.000 claims description 7
102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 7
201000010901 lateral sclerosis Diseases 0.000 claims description 7
208000005264 motor neuron disease Diseases 0.000 claims description 7
108010050904 Interferons Proteins 0.000 claims description 6
102000014150 Interferons Human genes 0.000 claims description 6
230000000926 neurological effect Effects 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 5
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 5
241000282412 Homo Species 0.000 claims description 5
210000003169 central nervous system Anatomy 0.000 claims description 5
210000001428 peripheral nervous system Anatomy 0.000 claims description 5
230000002792 vascular Effects 0.000 claims description 5
201000001320 Atherosclerosis Diseases 0.000 claims description 4
102000009024 Epidermal Growth Factor Human genes 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
102000036693 Thrombopoietin Human genes 0.000 claims description 4
108010041111 Thrombopoietin Proteins 0.000 claims description 4
238000010322 bone marrow transplantation Methods 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
201000006417 multiple sclerosis Diseases 0.000 claims description 4
230000000472 traumatic effect Effects 0.000 claims description 4
210000004504 adult stem cell Anatomy 0.000 claims description 3
239000003446 ligand Substances 0.000 claims description 3
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
101100175600 Zea mays SH2 gene Proteins 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
238000002399 angioplasty Methods 0.000 claims description 2
230000036039 immunity Effects 0.000 claims description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 claims 2
102000007644 Colony-Stimulating Factors Human genes 0.000 claims 2
229940079322 interferon Drugs 0.000 claims 2
238000012986 modification Methods 0.000 claims 2
230000004048 modification Effects 0.000 claims 2
102000019034 Chemokines Human genes 0.000 claims 1
108010012236 Chemokines Proteins 0.000 claims 1
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims 1
108010002386 Interleukin-3 Proteins 0.000 claims 1
102100039064 Interleukin-3 Human genes 0.000 claims 1
238000007675 cardiac surgery Methods 0.000 claims 1
238000002054 transplantation Methods 0.000 abstract description 22
230000001225 therapeutic effect Effects 0.000 abstract description 18
238000011160 research Methods 0.000 abstract description 11
210000001519 tissue Anatomy 0.000 description 54
210000004991 placental stem cell Anatomy 0.000 description 39
230000006698 induction Effects 0.000 description 30
210000000056 organ Anatomy 0.000 description 28
108090000623 proteins and genes Proteins 0.000 description 22
230000010412 perfusion Effects 0.000 description 21
239000002609 medium Substances 0.000 description 19
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 16
230000003394 haemopoietic effect Effects 0.000 description 16
210000004940 nucleus Anatomy 0.000 description 15
206010028980 Neoplasm Diseases 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
210000002308 embryonic cell Anatomy 0.000 description 14
210000002569 neuron Anatomy 0.000 description 14
210000002901 mesenchymal stem cell Anatomy 0.000 description 13
239000008194 pharmaceutical composition Substances 0.000 description 13
238000004458 analytical method Methods 0.000 description 12
230000014509 gene expression Effects 0.000 description 12
238000001802 infusion Methods 0.000 description 12
238000002955 isolation Methods 0.000 description 12
238000002512 chemotherapy Methods 0.000 description 11
239000012530 fluid Substances 0.000 description 11
230000008439 repair process Effects 0.000 description 11
102400000345 Angiotensin-2 Human genes 0.000 description 10
101800000733 Angiotensin-2 Proteins 0.000 description 10
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 10
229950006323 angiotensin ii Drugs 0.000 description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
210000002894 multi-fate stem cell Anatomy 0.000 description 10
239000013589 supplement Substances 0.000 description 10
230000009469 supplementation Effects 0.000 description 10
102400000344 Angiotensin-1 Human genes 0.000 description 9
101800000734 Angiotensin-1 Proteins 0.000 description 9
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 9
230000001464 adherent effect Effects 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
230000001143 conditioned effect Effects 0.000 description 9
239000013598 vector Substances 0.000 description 9
108700019146 Transgenes Proteins 0.000 description 8
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
229940104302 cytosine Drugs 0.000 description 8
229960003957 dexamethasone Drugs 0.000 description 8
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
230000006801 homologous recombination Effects 0.000 description 8
238000002744 homologous recombination Methods 0.000 description 8
210000001778 pluripotent stem cell Anatomy 0.000 description 8
238000011084 recovery Methods 0.000 description 8
229930002330 retinoic acid Natural products 0.000 description 8
230000001502 supplementing effect Effects 0.000 description 8
229960001727 tretinoin Drugs 0.000 description 8
102400001368 Epidermal growth factor Human genes 0.000 description 7
108090001061 Insulin Proteins 0.000 description 7
238000000684 flow cytometry Methods 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
102000004877 Insulin Human genes 0.000 description 6
102000004889 Interleukin-6 Human genes 0.000 description 6
108090001005 Interleukin-6 Proteins 0.000 description 6
208000012902 Nervous system disease Diseases 0.000 description 6
239000004743 Polypropylene Substances 0.000 description 6
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 6
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
210000001612 chondrocyte Anatomy 0.000 description 6
238000000605 extraction Methods 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
208000007345 glycogen storage disease Diseases 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
210000003494 hepatocyte Anatomy 0.000 description 6
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
210000005087 mononuclear cell Anatomy 0.000 description 6
210000003205 muscle Anatomy 0.000 description 6
239000008188 pellet Substances 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
108010035532 Collagen Proteins 0.000 description 5
102000008186 Collagen Human genes 0.000 description 5
208000025966 Neurological disease Diseases 0.000 description 5
210000003425 amniotic epithelial cell Anatomy 0.000 description 5
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
210000000845 cartilage Anatomy 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
229920001436 collagen Polymers 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
229940125396 insulin Drugs 0.000 description 5
229940047122 interleukins Drugs 0.000 description 5
238000012423 maintenance Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
210000001525 retina Anatomy 0.000 description 5
239000000243 solution Substances 0.000 description 5
210000000278 spinal cord Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 4
DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
102000049556 Jagged-1 Human genes 0.000 description 4
108700003486 Jagged-1 Proteins 0.000 description 4
201000011252 Phenylketonuria Diseases 0.000 description 4
208000022292 Tay-Sachs disease Diseases 0.000 description 4
108090000097 Transforming growth factor beta-3 Proteins 0.000 description 4
102400000398 Transforming growth factor beta-3 Human genes 0.000 description 4
210000001789 adipocyte Anatomy 0.000 description 4
230000011759 adipose tissue development Effects 0.000 description 4
230000003190 augmentative effect Effects 0.000 description 4
210000002459 blastocyst Anatomy 0.000 description 4
208000016532 chronic granulomatous disease Diseases 0.000 description 4
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000002257 embryonic structure Anatomy 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
230000005484 gravity Effects 0.000 description 4
210000002064 heart cell Anatomy 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000010354 integration Effects 0.000 description 4
229940047124 interferons Drugs 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
210000004165 myocardium Anatomy 0.000 description 4
210000004409 osteocyte Anatomy 0.000 description 4
230000002188 osteogenic effect Effects 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
230000005855 radiation Effects 0.000 description 4
238000009256 replacement therapy Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 3
201000011452 Adrenoleukodystrophy Diseases 0.000 description 3
102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108010029697 CD40 Ligand Proteins 0.000 description 3
102100032937 CD40 ligand Human genes 0.000 description 3
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
206010010356 Congenital anomaly Diseases 0.000 description 3
201000003883 Cystic fibrosis Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 3
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 3
102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 3
101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 3
208000009796 Gangliosidoses Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010053185 Glycogen storage disease type II Diseases 0.000 description 3
229920002971 Heparan sulfate Polymers 0.000 description 3
206010020365 Homocystinuria Diseases 0.000 description 3
208000026350 Inborn Genetic disease Diseases 0.000 description 3
102100037850 Interferon gamma Human genes 0.000 description 3
102000006992 Interferon-alpha Human genes 0.000 description 3
108010047761 Interferon-alpha Proteins 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
102000004388 Interleukin-4 Human genes 0.000 description 3
108010085895 Laminin Proteins 0.000 description 3
208000015439 Lysosomal storage disease Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
208000030162 Maple syrup disease Diseases 0.000 description 3
108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 3
208000002678 Mucopolysaccharidoses Diseases 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
208000013234 Pearson syndrome Diseases 0.000 description 3
241000097929 Porphyria Species 0.000 description 3
208000010642 Porphyrias Diseases 0.000 description 3
102000003946 Prolactin Human genes 0.000 description 3
108010057464 Prolactin Proteins 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 3
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
230000002293 adipogenic effect Effects 0.000 description 3
239000003098 androgen Substances 0.000 description 3
229940030486 androgens Drugs 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
210000000721 basilar membrane Anatomy 0.000 description 3
238000004820 blood count Methods 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
230000022159 cartilage development Effects 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
230000002648 chondrogenic effect Effects 0.000 description 3
230000003750 conditioning effect Effects 0.000 description 3
230000007547 defect Effects 0.000 description 3
108700041286 delta Proteins 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000002224 dissection Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
210000003754 fetus Anatomy 0.000 description 3
238000007710 freezing Methods 0.000 description 3
230000008014 freezing Effects 0.000 description 3
208000016361 genetic disease Diseases 0.000 description 3
201000004502 glycogen storage disease II Diseases 0.000 description 3
238000003306 harvesting Methods 0.000 description 3
230000036541 health Effects 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
229960000890 hydrocortisone Drugs 0.000 description 3
208000003532 hypothyroidism Diseases 0.000 description 3
230000002989 hypothyroidism Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
208000024393 maple syrup urine disease Diseases 0.000 description 3
108010082117 matrigel Proteins 0.000 description 3
230000004089 microcirculation Effects 0.000 description 3
238000000520 microinjection Methods 0.000 description 3
206010028093 mucopolysaccharidosis Diseases 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
230000035772 mutation Effects 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
230000001114 myogenic effect Effects 0.000 description 3
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
210000001706 olfactory mucosa Anatomy 0.000 description 3
210000002220 organoid Anatomy 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
229940097325 prolactin Drugs 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000012679 serum free medium Substances 0.000 description 3
208000007056 sickle cell anemia Diseases 0.000 description 3
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
229940035722 triiodothyronine Drugs 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
210000003454 tympanic membrane Anatomy 0.000 description 3
230000035899 viability Effects 0.000 description 3
230000036642 wellbeing Effects 0.000 description 3
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
101150116411 AGTR2 gene Proteins 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
208000000044 Amnesia Diseases 0.000 description 2
208000032467 Aplastic anaemia Diseases 0.000 description 2
239000004255 Butylated hydroxyanisole Substances 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
208000010496 Heart Arrest Diseases 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
208000001019 Inborn Errors Metabolism Diseases 0.000 description 2
MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
208000006136 Leigh Disease Diseases 0.000 description 2
208000017507 Leigh syndrome Diseases 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
208000026139 Memory disease Diseases 0.000 description 2
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000008221 Superoxide Dismutase-1 Human genes 0.000 description 2
108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000004338 Transferrin Human genes 0.000 description 2
108090000901 Transferrin Proteins 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
230000032683 aging Effects 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
210000001691 amnion Anatomy 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000002617 apheresis Methods 0.000 description 2
230000003416 augmentation Effects 0.000 description 2
229940088007 benadryl Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000002449 bone cell Anatomy 0.000 description 2
235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
229940043253 butylated hydroxyanisole Drugs 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
206010008129 cerebral palsy Diseases 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
230000003920 cognitive function Effects 0.000 description 2
230000005757 colony formation Effects 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
238000005138 cryopreservation Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000000432 density-gradient centrifugation Methods 0.000 description 2
229960000520 diphenhydramine Drugs 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
230000001037 epileptic effect Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000012239 gene modification Methods 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
210000005003 heart tissue Anatomy 0.000 description 2
208000034737 hemoglobinopathy Diseases 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
208000016245 inborn errors of metabolism Diseases 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
208000018337 inherited hemoglobinopathy Diseases 0.000 description 2
208000015978 inherited metabolic disease Diseases 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000007726 management method Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000008774 maternal effect Effects 0.000 description 2
230000006984 memory degeneration Effects 0.000 description 2
208000023060 memory loss Diseases 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000002161 motor neuron Anatomy 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000001272 neurogenic effect Effects 0.000 description 2
230000004031 neuronal differentiation Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
230000009818 osteogenic differentiation Effects 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
238000004321 preservation Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000036387 respiratory rate Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
230000037380 skin damage Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
239000012581 transferrin Substances 0.000 description 2
229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
201000011296 tyrosinemia Diseases 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
230000000982 vasogenic effect Effects 0.000 description 2
239000002699 waste material Substances 0.000 description 2
CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
101150028074 2 gene Proteins 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
BFFPVEVGHKMWLT-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurin-6-one Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2 BFFPVEVGHKMWLT-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
FHYNZKLNCPUNEU-UHFFFAOYSA-N 4-[(3,4-dihydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(O)=C1 FHYNZKLNCPUNEU-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000004881 Angiotensinogen Human genes 0.000 description 1
108090001067 Angiotensinogen Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000218645 Cedrus Species 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
208000015178 Hurler syndrome Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241000764238 Isis Species 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
102000008730 Nestin Human genes 0.000 description 1
108010088225 Nestin Proteins 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
102100035194 Placenta growth factor Human genes 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000004115 adherent culture Methods 0.000 description 1
230000009815 adipogenic differentiation Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940127079 antineoplastic immunimodulatory agent Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
230000009816 chondrogenic differentiation Effects 0.000 description 1
210000001136 chorion Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
230000002338 cryopreservative effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000002641 enzyme replacement therapy Methods 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000007773 growth pattern Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009681 mesenchymal cell proliferation Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
230000004070 myogenic differentiation Effects 0.000 description 1
230000009707 neogenesis Effects 0.000 description 1
210000005055 nestin Anatomy 0.000 description 1
210000003757 neuroblast Anatomy 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000003256 osteocytic effect Effects 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229960000688 pomalidomide Drugs 0.000 description 1
UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
208000032253 retinal ischemia Diseases 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000002976 reverse transcriptase assay Methods 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
IMRYETFJNLKUHK-UHFFFAOYSA-N traseolide Chemical compound CC1=C(C(C)=O)C=C2C(C(C)C)C(C)C(C)(C)C2=C1 IMRYETFJNLKUHK-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000001644 umbilical artery Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000003934 vacuole Anatomy 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0462—Placental blood, umbilical cord blood

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Virology (AREA)
Diabetes (AREA)
General Engineering & Computer Science (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Psychiatry (AREA)

MXPA04007732A 2002-02-13 2003-02-13 Celulas madre similares a las embrionarias, derivadas de la placenta de mamiferos despues del parto y usos y metodos de tratamiento usando dichas celulas. MXPA04007732A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/076,180 US20030032179A1 (en)	2000-12-06	2002-02-13	Post-partum mammalian placenta, its use and placental stem cells therefrom
US43729202P	2002-12-31	2002-12-31
PCT/US2003/004539 WO2003068937A2 (fr)	2002-02-13	2003-02-13	Cellules souches de type embryonnaire derivees de placenta mammalien post-partum, utilisations, et procedes de traitement a base de cellules de ce type

Publications (1)

Publication Number	Publication Date
MXPA04007732A true MXPA04007732A (es)	2004-10-15

Family

ID=42186393

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA04007732A MXPA04007732A (es)	2002-02-13	2003-02-13	Celulas madre similares a las embrionarias, derivadas de la placenta de mamiferos despues del parto y usos y metodos de tratamiento usando dichas celulas.

Country Status (10)

Country	Link
EP (1)	EP1482787A4 (fr)
JP (2)	JP2005517402A (fr)
KR (2)	KR101176146B1 (fr)
AU (2)	AU2003216286B2 (fr)
CA (1)	CA2476553A1 (fr)
IL (2)	IL163439A (fr)
MX (1)	MXPA04007732A (fr)
NZ (1)	NZ534643A (fr)
WO (1)	WO2003068937A2 (fr)
ZA (1)	ZA200406356B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA03005014A (es)	2000-12-06	2004-09-10	Robert J Hariri	Metodo para recolectar celulas madres de la placenta.
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
NZ566132A (en) *	2003-02-13	2009-09-25	Anthrogenesis Corp	Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
US8790637B2 (en)	2003-06-27	2014-07-29	DePuy Synthes Products, LLC	Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en)	2003-06-27	2017-02-21	DePuy Synthes Products, Inc.	Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en)	2003-06-27	2017-03-14	DePuy Synthes Products, Inc.	Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
ES2569780T3 (es) *	2003-06-27	2016-05-12	DePuy Synthes Products, Inc.	Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
US8491883B2 (en) *	2003-06-27	2013-07-23	Advanced Technologies And Regenerative Medicine, Llc	Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US7875272B2 (en)	2003-06-27	2011-01-25	Ethicon, Incorporated	Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8088585B2 (en)	2003-10-31	2012-01-03	Children's Medical Center Corporation	Methods for purifying hematopoietic stem cells
WO2005073366A1 (fr) *	2004-01-30	2005-08-11	Lifecord Inc.	Methode d'isolement et de culture de cellules souches multipotentes a partir de sang du cordon ombilical et procede pour induire leur differenciation
US7622108B2 (en)	2004-04-23	2009-11-24	Bioe, Inc.	Multi-lineage progenitor cells
US7670596B2 (en) *	2004-04-23	2010-03-02	Bioe, Inc.	Multi-lineage progenitor cells
WO2005112959A2 (fr) *	2004-05-17	2005-12-01	Regents Of The University Of Minnesota	Utilisation de cellules souches de cordon ombilical pour traiter un evenement ischemique
WO2006015214A2 (fr) *	2004-07-29	2006-02-09	Steenblock Research Institute, Inc.	Composition de cellules souches de cordon ombilical et methode de traitement de maladies neurologiques
CA2504451A1 (fr) *	2004-08-10	2006-02-10	Geron Corporation	Vaccins a cellules dendritiques faits de cellules souches embryonnaires pour le traitement du cancer
NZ553695A (en)	2004-08-16	2009-10-30	Cellres Corp Pte Ltd	Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
CA2589063C (fr)	2004-12-23	2016-08-09	DePuy Synthes Products, Inc.	Traitement de la maladie de parkinson et de troubles associes au moyen de cellules derivees postnatales
EP1831355A2 (fr) *	2004-12-23	2007-09-12	Ethicon, Inc.	Reparation et regeneration de tissus mous au moyen de cellules derivees du post-partum et produits cellulaires
WO2006071773A2 (fr) *	2004-12-23	2006-07-06	Ethicon Incoporated	Traitement de maladies osteochondrales utilisant des cellules derivees de post-partum et des produits de ceux-ci
DE602005017812D1 (de) *	2005-08-26	2009-12-31	Seoul Nat Univ Ind Foundation	Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit
JP2007106760A (ja) *	2005-09-16	2007-04-26	Kenji Yoshida	造血幹細胞増殖剤
WO2007032566A1 (fr) *	2005-09-16	2007-03-22	Kenji Yoshida	Proliferateur de cellules souches hematopoietiques
ES2454021T3 (es)	2005-10-05	2014-04-09	The Board Of Trustees Of The University Of Illinois	Células madre de tipo embrionario aisladas de sangre de cordón umbilical humano
US9388382B2 (en)	2005-10-05	2016-07-12	The Board Of Trustees Of The University Of Illinois	Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
EP1957633B1 (fr) *	2005-10-13	2013-12-18	Anthrogenesis Corporation	Immunomodulation realisee avec des cellules souches placentaires
AU2006304274B2 (en)	2005-10-13	2012-08-16	Celularity Inc.	Production of oligodendrocytes from placenta-derived stem cells
EP2206724A1 (fr) *	2005-12-13	2010-07-14	Kyoto University	Facteur de reprogrammation nucléaire
US9175261B2 (en)	2005-12-16	2015-11-03	DePuy Synthes Products, Inc.	Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
CN101437576A (zh) *	2005-12-28	2009-05-20	伊西康公司	使用产后衍生细胞治疗外周血管疾病
US9125906B2 (en)	2005-12-28	2015-09-08	DePuy Synthes Products, Inc.	Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
AU2014201181B2 (en) *	2005-12-29	2017-07-20	Celularity Inc.	Placental stem cell populations
AU2006332679A1 (en) *	2005-12-29	2007-07-12	Anthrogenesis Corporation	Co-culture of placental stem cells and stem cells from a second source
US9598669B2 (en)	2005-12-29	2017-03-21	Anthrogenesis Corporation	Composition for collecting placental stem cells and methods of using the composition
KR20180105266A (ko)	2005-12-29	2018-09-27	안트로제네시스 코포레이션	태반 줄기 세포 집단
US9944900B2 (en)	2006-01-18	2018-04-17	Hemacell Perfusion	Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
CA2646491A1 (fr) *	2006-04-17	2007-10-25	Bioe, Inc.	Differenciation des cellules progenitrices a lignees multiples et cellules epitheliales respiratoires
CA3103505C (fr) *	2006-05-11	2023-07-04	Celularity Inc.	Procedes destines a prelever et a utiliser des cellules souches de sang placentaire de cordon ombilical
CA2666789C (fr)	2006-10-18	2016-11-22	Yong Zhao	Cellules souches de type embryonnaire derivees du sang peripherique d'un etre humain adulte et procedes d'utilisation associes
KR100812544B1 (ko) *	2006-10-19	2008-03-13	재단법인서울대학교산학협력재단	제대혈 유래 다분화능 줄기세포 및 이를 함유하는 허혈성괴사질환 치료용 세포치료제
NZ606814A (en) *	2006-10-23	2014-10-31	Anthrogenesis Corp	Methods and compositions for treatment of bone defects with placental cell populations
JP2010518812A (ja)	2007-02-12	2010-06-03	アンスロジェネシスコーポレーション	接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
CN103356710A (zh) *	2007-02-12	2013-10-23	人类起源公司	利用胎盘干细胞治疗炎性疾病
AU2014203165B2 (en) *	2007-02-12	2016-08-11	Celularity Inc.	Treatment of inflammatory diseases using placental stem cells
US8673547B2 (en)	2007-03-08	2014-03-18	Hemacell Perfusion, Inc.	Method for isolation of afterbirth derived cells
US9200253B1 (en)	2007-08-06	2015-12-01	Anthrogenesis Corporation	Method of producing erythrocytes
ES2392729T5 (es)	2007-09-19	2015-08-28	Pluristem Ltd.	Células adherentes de tejidos adiposos o de placenta y uso de las mismas en terapia
AU2013267050B2 (en) *	2007-09-19	2016-01-07	Pluristem Ltd.	Adherent cells from adipose or placenta tissues and use thereof in therapy
KR20200136051A (ko) *	2007-09-26	2020-12-04	안트로제네시스 코포레이션	인간 태반 관류액으로부터의 혈관형성 세포
EP2203176B1 (fr)	2007-09-28	2014-11-26	Anthrogenesis Corporation	Elimination des tumeurs au moyen d'un perfusat placentaire humain et de cellules tueuses naturelles intermediaires provenant d'un placenta humain
AU2008325142A1 (en) *	2007-11-07	2009-05-14	Anthrogenesis Corporation	Use of umbilical cord blood in the treatment of premature birth complications
NZ591292A (en)	2008-08-20	2012-10-26	Anthrogenesis Corp	Improved cell composition and methods of making the same
US10557116B2 (en)	2008-12-19	2020-02-11	DePuy Synthes Products, Inc.	Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en)	2008-12-19	2019-01-15	DePuy Synthes Products, Inc.	Conditioned media and methods of making a conditioned media
PL2411504T3 (pl)	2009-03-26	2017-10-31	Depuy Synthes Products Inc	Komórki ludzkiej tkanki pępowinowej jako terapia choroby Alzheimera
EP2449095A1 (fr)	2009-07-02	2012-05-09	Anthrogenesis Corporation	Procédé pour produire des érythrocytes sans cellules nourricières
KR20120127468A (ko)	2010-01-26	2012-11-21	스템 셀즈 스핀 에스 에이	성장하는 사슴뿔에서 유래한 줄기세포로부터의 세포 균질현탁액, 이의 수득 방법 및 이의 용도
CA2787992A1 (fr)	2010-01-26	2011-08-04	Anthrogenesis Corporation	Traitement de cancers associes aux os utilisant des cellules souches placentaires
PL2556145T3 (pl)	2010-04-07	2017-02-28	Anthrogenesis Corporation	Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
MX342995B (es)	2010-07-13	2016-10-21	Anthrogenesis Corp	Métodos de generar células asesinas naturales.
US8969315B2 (en)	2010-12-31	2015-03-03	Anthrogenesis Corporation	Enhancement of placental stem cell potency using modulatory RNA molecules
DK2714059T3 (en)	2011-06-01	2019-01-21	Celularity Inc	TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
KR101981450B1 (ko)	2011-12-23	2019-08-28	디퍼이 신테스 프로덕츠, 인코포레이티드	인간 제대 조직-유래된 세포의 검출
EP3622960A1 (fr)	2013-02-05	2020-03-18	Celularity, Inc.	Cellules tueuses naturelles placentaires
PT2968420T (pt) *	2013-03-14	2019-01-11	Celularity Inc	Utilização de células estaminais placentárias no tratamento de lesão renal aguda
CN105408472A (zh)	2013-03-15	2016-03-16	马卡斯凯尔·托莱夫·拉尔森	用于脐带血收集及细胞分离的细胞、方法和装置
ES2747951T3 (es)	2013-10-24	2020-03-12	Ospedale San Raffaele Srl	Método
US20180037867A1 (en)	2015-03-04	2018-02-08	Mesoblast International Sàrl	Cell culture method for mesenchymal stem cells
FR3035407B1 (fr)	2015-04-23	2022-06-17	Francais Du Sang Ets	Procede de conservation de cellules, tissus ou organes en hypothermie
FR3040860B1 (fr) *	2015-09-10	2020-05-15	Universite de Bordeaux	Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique
US11542473B2 (en)	2016-10-21	2023-01-03	Amniotics Ab	Methods and compositions for generating hematopoietic cells
WO2020256628A1 (fr)	2019-06-20	2020-12-24	Amniotics Ab	Appareil de filtration de liquide amniotique
JP7714535B2 (ja)	2019-10-18	2025-07-29	アムニオティクス・アーベー	羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置
US12435308B2 (en)	2020-11-06	2025-10-07	Amniotics Ab	Immunomodulation by amniotic fluid mesenchymal stem cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5004681B1 (en) *	1987-11-12	2000-04-11	Biocyte Corp	Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
GB9308271D0 (en) *	1993-04-21	1993-06-02	Univ Edinburgh	Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
ES2180665T3 (es) *	1994-11-16	2003-02-16	Amgen Inc	Uso de factor de celulas madre y de receptor soluble de interleuquina-6 para la expansion ex-vivo de celulas hematopoyeticas multipotenciales.
US5916202A (en) *	1996-08-30	1999-06-29	Haswell; John N.	Umbilical cord blood collection
AU7611500A (en) *	1999-09-24	2001-04-24	Abt Holding Company	Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
MXPA03005014A (es) *	2000-12-06	2004-09-10	Robert J Hariri	Metodo para recolectar celulas madres de la placenta.
AU2002251935B2 (en) *	2001-02-14	2007-11-29	Celularity Inc.	Post-partum mammalian placenta, its use and placental stem cells therefrom

2003
- 2003-02-13 EP EP03739817A patent/EP1482787A4/fr not_active Ceased
- 2003-02-13 KR KR1020047012604A patent/KR101176146B1/ko not_active Expired - Lifetime
- 2003-02-13 KR KR1020117003297A patent/KR20110036114A/ko not_active Ceased
- 2003-02-13 NZ NZ534643A patent/NZ534643A/en not_active IP Right Cessation
- 2003-02-13 JP JP2003568052A patent/JP2005517402A/ja active Pending
- 2003-02-13 CA CA002476553A patent/CA2476553A1/fr not_active Abandoned
- 2003-02-13 MX MXPA04007732A patent/MXPA04007732A/es active IP Right Grant
- 2003-02-13 AU AU2003216286A patent/AU2003216286B2/en not_active Expired
- 2003-02-13 WO PCT/US2003/004539 patent/WO2003068937A2/fr not_active Ceased
2004
- 2004-08-10 IL IL163439A patent/IL163439A/en active IP Right Grant
- 2004-08-11 ZA ZA200406356A patent/ZA200406356B/en unknown
2008
- 2008-11-25 AU AU2008249204A patent/AU2008249204B2/en not_active Expired
2009
- 2009-11-12 JP JP2009258822A patent/JP2010059193A/ja active Pending
2010
- 2010-08-24 IL IL207763A patent/IL207763A/en active IP Right Grant

Also Published As

Publication number	Publication date
WO2003068937A2 (fr)	2003-08-21
KR20110036114A (ko)	2011-04-06
KR101176146B1 (ko)	2012-08-22
AU2003216286A1 (en)	2003-09-04
AU2003216286B2 (en)	2008-08-28
IL163439A (en)	2011-03-31
WO2003068937A3 (fr)	2004-04-22
EP1482787A4 (fr)	2006-02-15
CA2476553A1 (fr)	2003-08-21
AU2008249204A1 (en)	2008-12-18
EP1482787A2 (fr)	2004-12-08
IL207763A (en)	2014-07-31
KR20040094426A (ko)	2004-11-09
ZA200406356B (en)	2006-06-28
IL207763A0 (en)	2010-12-30
JP2010059193A (ja)	2010-03-18
JP2005517402A (ja)	2005-06-16
AU2008249204B2 (en)	2011-03-10
NZ534643A (en)	2010-06-25

Legal Events

Date	Code	Title	Description
2009-09-23	FG	Grant or registration

Publication	Publication Date	Title
US7311905B2 (en)	2007-12-25	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2003216286B2 (en)	2008-08-28	Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
AU2004212009B2 (en)	2010-07-29	Use of umbilical cord blood to treat individuals having a disease, disorder or condition
EP2316919B1 (fr)	2015-10-07	Placenta post-gravidique de mammifère, son utilisation et céllules souches placentaires correspondantes
AU2011202711B2 (en)	2012-02-02	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
NZ579705A (en)	2011-07-29	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20170224739A1 (en)	2017-08-10	Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
HK1154756A (en)	2012-05-04	Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
HK1145939A (en)	2011-05-13	Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
HK1154334A (en)	2012-04-20	Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
HK1156965B (en)	2016-09-30	Post-partum mammalian placenta, its use and placental stem cells therefrom
HK1157384A1 (en)	2012-06-29	Post-partum mammalian placenta, its use and placental stem cells therefrom
HK1157386A (en)	2012-06-29	Post-partum mammalian placenta, its use and placental stem cells therefrom
HK1157384B (en)	2015-07-17	Post-partum mammalian placenta, its use and placental stem cells therefrom
HK1157383B (en)	2016-05-27	Post-partum mammalian placenta, its use and placental stem cells therefrom